XML 29 R22.htm IDEA: XBRL DOCUMENT v3.25.3
Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2025
Accounting Policies [Abstract]  
Schedule of Segment Reporting

 

 

For the Three Months
Ended September 30,

 

 

For the Nine Months
Ended September 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Tegoprubart - kidney transplantation programs

 

$

9,363

 

 

$

10,167

 

 

$

26,600

 

 

$

19,284

 

Tegoprubart - other development programs

 

 

 

 

 

14

 

 

 

(168

)

 

 

430

 

Manufacturing

 

 

1,736

 

 

 

4,252

 

 

 

11,031

 

 

 

7,826

 

Personnel-related

 

 

3,664

 

 

 

2,524

 

 

 

10,808

 

 

 

7,400

 

Stock-based compensation

 

 

2,428

 

 

 

1,783

 

 

 

7,986

 

 

 

6,540

 

Other operating expenses

 

 

1,879

 

 

 

1,770

 

 

 

5,510

 

 

 

4,401

 

Total operating expenses

 

 

19,070

 

 

 

20,510

 

 

 

61,767

 

 

 

45,881

 

Loss from operations

 

 

(19,070

)

 

 

(20,510

)

 

 

(61,767

)

 

 

(45,881

)

Other income, net

 

 

1,047

 

 

 

1,042

 

 

 

3,680

 

 

 

2,485

 

Change in fair value of warrant liabilities

 

 

564

 

 

 

96,439

 

 

 

22,917

 

 

 

51,829

 

Segment and net income (loss)

 

$

(17,459

)

 

$

76,971

 

 

$

(35,170

)

 

$

8,433